Remibrutinib vs Teriflunomide in RMS (REMODEL-1)

Market
100%75%50%25%0%Apr 13 • YES 56.0%Apr 13Apr 13 • YES 86.8%Apr 13
Trade

Will the results be positive?

Paper Trading
DetailsModel PositionsModel SnapshotsOracle
Details
Primary Completion
4/30/26
Study Completion
10/30/30
Company
Novartis Pharmaceuticals
Ticker
NVS
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
1,001
Volume
$389K
NCT
NCT05147220
Drug Description
REMODEL-1 is a randomized, double-blind, double-dummy Phase 3 study comparing oral remibrutinib with teriflunomide in adults with relapsing multiple sclerosis. The primary endpoint is annualized relapse rate over the Core Part of up to 30 months, followed by an open-label remibrutinib extension for eligible participants.